糖尿病性神経障害の世界市場レポート 2025年

糖尿病性神経障害の市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR10.4％で93億米ドルに成長します。予測期間の成長は、神経画像診断の進歩、患者中心のケアアプローチ、臨床試験の拡大、糖尿病患者の継続的な増加、精密医療アプローチ、再生医療の拡大、患者擁護と支援プログラムに起因しています。予測期間における主な動向としては、医学研究における共同研究、デジタルヘルスソリューション、診断技術の進歩、神経保護療法、個別化治療戦略、人工知能の統合などが挙げられます。

糖尿病有病率の増加が予測され、糖尿病性神経障害市場の大幅な成長が見込まれます。糖尿病は、グルコースの適切な使用と貯蔵ができないことを特徴とする持続的な病態であり、糖尿病性神経障害として知られる様々な形態の神経損傷を引き起こします。国際糖尿病連合が2022年8月に発表したIDF Diabetes Atlas報告書で強調されているように、糖尿病関連死による世界の死亡者数は2021年には670万人に達し、これは5秒に1人の致死率に相当します。現在、世界には約5億3,700万人の糖尿病患者（20～79歳）がおり、2030年には6億4,300万人、2045年には7億8,300万人に急増すると予測されています。このような糖尿病有病率の増加は、糖尿病性神経障害市場の急成長に大きく寄与しています。

高齢者人口の割合の拡大は、糖尿病性神経障害市場の成長を促進します。高齢になるにつれて、糖尿病や神経障害を含む合併症を開発する可能性が高まります。糖尿病性神経障害には、糖尿病患者によく見られる神経障害が含まれ、患部のしびれ、ピリピリ感、痛みなどの症状を引き起こします。2022年10月の世界保健機関（WHO）の予測によると、2030年には世界の6人に1人が60歳以上の高齢者となり、60歳以上の人口は2020年の10億人から14億人に急増します。2050年には、世界の60歳以上の人口は2倍の21億人に達し、80歳以上の人口は3倍の4億2,600万人になると予想されています。このような高齢化により、糖尿病性神経障害治療に対する需要が高まると予想されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の糖尿病性神経障害市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の糖尿病性神経障害市場：成長率分析
• 世界の糖尿病性神経障害市場の実績：規模と成長、2019～2024年
• 世界の糖尿病性神経障害市場の予測：規模と成長、2024～2029年、2034年
• 世界の糖尿病性神経障害総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の糖尿病性神経障害市場：障害別、実績と予測、2019～2024年、2024～2029年、2034年
• 末梢神経障害
• 自律神経障害
• 近位神経障害
• 局所神経障害
• 世界の糖尿病性神経障害市場：薬剤クラス別、実績と予測、2019～2024年、2024～2029年、2034年
• 鎮痛剤
• 抗うつ薬
• 抗痙攣薬
• その他
• 世界の糖尿病性神経障害市場：治療別、実績と予測、2019～2024年、2024～2029年、2034年
• 薬物治療
• 放射線治療
• 理学療法
• その他
• 世界の糖尿病性神経障害市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• オンライン
• オフライン
• 世界の糖尿病性神経障害市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• 専門クリニック
• その他
• 世界の糖尿病性神経障害市場：末梢神経障害のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 遠位対称性神経障害
• 単神経障害
• 多発性神経障害
• 世界の糖尿病性神経障害市場：自律神経障害のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 心血管自律神経障害
• 消化管自律神経障害
• 泌尿生殖器自律神経障害
• 世界の糖尿病性神経障害市場：近位神経障害のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 糖尿病性筋萎縮症
• 腰仙部神経叢障害
• 世界の糖尿病性神経障害市場：局所神経障害のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 脳神経障害
• 頸椎神経根症
• その他

第7章 地域別・国別分析

• 世界の糖尿病性神経障害市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の糖尿病性神経障害市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 糖尿病性神経障害市場：競合情勢
• 糖尿病性神経障害市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • Daiichi Sankyo Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Depomed Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• F. Hoffmann-La Roche AG
• NeuroMetrix Inc
• Lupin Limited
• Novartis AG
• Boehringer Ingelheim
• Regenacy Pharmaceuticals Inc.
• Merck & Co. Inc.
• Sanofi S.A.
• Teva Pharmaceutical Industries Ltd.
• AstraZeneca plc
• Bayer AG
• Bristol-Myers Squibb Company
• Merck KGaA
• Novo Nordisk A/S
• Takeda Pharmaceutical Company Limited

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 糖尿病性神経障害市場2029年：新たな機会を提供する国
• 糖尿病性神経障害市場2029年：新たな機会を提供するセグメント
• 糖尿病性神経障害市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Diabetic neuropathy is a form of nerve damage that can affect individuals with diabetes, often resulting from elevated blood sugar levels that cause damage to blood vessels. This condition can impact various nerves in the body, including those in the feet, organs, and muscles.

The primary types of diabetic neuropathy include peripheral neuropathy, autonomic neuropathy, proximal neuropathy, and focal neuropathy. Peripheral neuropathy occurs when the peripheral nerves, responsible for transmitting information between the brain, spinal cord, and the rest of the body, are damaged. Treatment for diabetic neuropathy involves various classes of drugs, such as analgesics, anti-depressants, anti-convulsant, and others, along with approaches such as drug treatment, radiotherapy, physiotherapy, and more. These treatments are made available through different distribution channels, including online and offline channels, and are utilized in settings such as hospitals, specialty clinics, and others.

The diabetic neuropathy market research report is one of a series of new reports from The Business Research Company that provides diabetic neuropathy market statistics, including diabetic neuropathy industry global market size, regional shares, competitors with a diabetic neuropathy market share, detailed diabetic neuropathy market segments, market trends and opportunities, and any further data you may need to thrive in the diabetic neuropathy industry. This diabetic neuropathy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The diabetic neuropathy market size has grown strongly in recent years. It will grow from $5.79 billion in 2024 to $6.27 billion in 2025 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to rising global diabetes prevalence, increased awareness and diagnosis, advancements in diabetic care, growing healthcare expenditure, research and development investments, patient education initiatives.

The diabetic neuropathy market size is expected to see rapid growth in the next few years. It will grow to $9.3 billion in 2029 at a compound annual growth rate (CAGR) of 10.4%. The growth in the forecast period can be attributed to advancements in neuroimaging, patient-centric care approaches, expansion of clinical trials, continued rise in diabetes cases, precision medicine approaches, expansion of regenerative medicine, patient advocacy and support programs. Major trends in the forecast period include collaborative efforts in medical research, digital health solutions, advancements in diagnostic technologies, neuroprotective therapies, personalized treatment strategies, integration of artificial intelligence.

The projected increase in diabetes prevalence is anticipated to drive substantial growth within the diabetic neuropathy market. Diabetes, a persistent condition characterized by the body's inability to adequately use and store glucose, leads to various forms of nerve damage known as diabetic neuropathy. As highlighted in the IDF Diabetes Atlas report released by the International Diabetes Federation in August 2022, the global toll from diabetes-related deaths amounted to 6.7 million in 2021, equating to one fatality every five seconds. Presently, there are approximately 537 million adults (aged 20-79) living with diabetes worldwide, a figure predicted to surge to 643 million by 2030 and 783 million by 2045. This escalating diabetes prevalence significantly contributes to the burgeoning diabetic neuropathy market.

The expanding proportion of the elderly population is poised to fuel the growth of the diabetic neuropathy market. As individuals age, the likelihood of developing diabetes and associated complications, including neuropathy, increases. Diabetic neuropathy encompasses nerve damage common in diabetic individuals, leading to symptoms such as numbness, tingling, and pain in affected areas. As per projections by the World Health Organization in October 2022, by 2030, one out of every six individuals globally will be aged 60 years or older, with the population of those aged 60 years and above set to surge from 1 billion in 2020 to 1.4 billion. By 2050, the worldwide population of individuals aged 60 years and older is expected to double, reaching 2.1 billion, with the number of individuals aged 80 years or older tripling to 426 million. This aging demographic is expected to drive demand for diabetic neuropathy treatments.

Major companies in the diabetic neuropathy market are developing advanced products, such as neuromodulation therapy devices, to improve treatment options for patients experiencing chronic pain linked to diabetic neuropathy. These devices provide non-invasive treatment by modulating nerve activity to alleviate pain, enhance nerve function, and promote healing in individuals with diabetic nerve damage. For example, in January 2024, Neuralace Medical, Inc., a US-based company specializing in non-drug pain management treatments, received approval from the Food and Drug Administration (FDA) for its Axon Therapy designed for Chronic Painful Diabetic Neuropathy (CPDN). This innovative device employs neuromodulation techniques to relieve pain associated with diabetic neuropathy, representing a significant advancement in pain management options for affected patients. The FDA clearance highlights the device's safety and efficacy, enabling Neuralace to proceed with commercialization and broaden access to effective treatment solutions for those suffering from CPDN.

Prominent companies within the diabetic neuropathy market are actively pursuing strategic partnerships and alliances to foster innovation and fortify their market positions. These alliances, formal agreements between multiple businesses, aim to leverage shared resources, knowledge, or expertise to achieve mutual objectives. For instance, in July 2022, Teva Pharmaceutical Industries Ltd., an Israel-based clinical-stage biopharmaceutical company, joined forces with NeuroFront Therapeutics Limited, a Hong Kong-based biotech firm, in an exclusive alliance and commercialization pact for Novaremed's pioneering non-opioid investigational drug, NRD.E1. This drug is specifically designed to treat diabetes-associated neuropathic pain and other related indications. This strategic collaboration enables the development and commercialization of an innovative therapy for neuropathic pain management.

In January 2022, Withings SA, a France-based consumer electronics company specializing in clinically validated smart health devices and associated apps, completed the acquisition of Impeto Medical SAS for an undisclosed sum. This strategic acquisition empowers Withings to integrate Impeto's cutting-edge technologies, including nerve tracking activity, into its product portfolio and services. Impeto Medical SAS, a France-based medical device company, manufactures tools for monitoring peripheral neuropathies to detect small fiber neuropathies in various diseases and conditions. This acquisition strengthens Withings' capabilities by incorporating advanced nerve tracking technologies, enhancing their offerings for neuropathy monitoring and management within their health devices and services lineup.

Major companies operating in the diabetic neuropathy market include Pfizer Inc., Eli Lilly and Company, Daiichi Sankyo Company Limited, Johnson & Johnson, Depomed Inc., F. Hoffmann-La Roche AG, NeuroMetrix Inc, Lupin Limited, Novartis AG, Boehringer Ingelheim, Regenacy Pharmaceuticals Inc., Merck & Co. Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Merck KGaA, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Zydus Cadila, Biogen Inc., Genentech Inc.

North America was the largest region in the diabetic neuropathy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the diabetic neuropathy market during the forecast period. The regions covered in the diabetic neuropathy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the diabetic neuropathy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The diabetic neuropathy market consists of sales of drugs such as anticonvulsants, pain medications, nerve growth factor inhibitors and other drugs that are used to treat the symptoms of nerve damage caused by diabetes. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Diabetic Neuropathy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on diabetic neuropathy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for diabetic neuropathy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The diabetic neuropathy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Disorder: Peripheral Neuropathy; Autonomic Neuropathy; Proximal Neuropathy; Focal Neuropathy
• 2) By Drug Class: Analgesics; Anti-Depressants; Anti-Convulsants; Other Drug Classes
• 3) By Treatment: Drug Treatment; Radiotherapy; Physiotherapy; Other Treatments
• 4) By Distribution Channel: Online Distribution; Offline Distribution
• 5) By End-User: Hospitals; Specialty Clinics; Other End-Users
• Subsegments:
• 1) By Peripheral Neuropathy: Distal Symmetric Neuropathy; Mononeuropathy; Polyneuropathy
• 2) By Autonomic Neuropathy: Cardiovascular Autonomic Neuropathy; Gastrointestinal Autonomic Neuropathy; Genitourinary Autonomic Neuropathy
• 3) By Proximal Neuropathy: Diabetic Amyotrophy; Lumbosacral Plexus Neuropathy
• 4) By Focal Neuropathy: Cranial Neuropathy; Cervical Radiculopathy; Other Focal Neuropathies
• Companies Mentioned: Pfizer Inc.; Eli Lilly and Company; Daiichi Sankyo Company Limited; Johnson & Johnson; Depomed Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Diabetic Neuropathy Market Characteristics

3. Diabetic Neuropathy Market Trends And Strategies

4. Diabetic Neuropathy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Diabetic Neuropathy Growth Analysis And Strategic Analysis Framework

• 5.1. Global Diabetic Neuropathy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Diabetic Neuropathy Market Growth Rate Analysis
• 5.4. Global Diabetic Neuropathy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Diabetic Neuropathy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Diabetic Neuropathy Total Addressable Market (TAM)

6. Diabetic Neuropathy Market Segmentation

• 6.1. Global Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Peripheral Neuropathy
• Autonomic Neuropathy
• Proximal Neuropathy
• Focal Neuropathy
• 6.2. Global Diabetic Neuropathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Analgesics
• Anti-Depressants
• Anti-consulvants
• Other Drug Classes
• 6.3. Global Diabetic Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Drug Treatment
• Radiotherapy
• Physiotherapy
• Other Treatments
• 6.4. Global Diabetic Neuropathy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Online Distribution
• Offline Distribution
• 6.5. Global Diabetic Neuropathy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Other End-users
• 6.6. Global Diabetic Neuropathy Market, Sub-Segmentation Of Peripheral Neuropathy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Distal Symmetric Neuropathy
• Mononeuropathy
• Polyneuropathy
• 6.7. Global Diabetic Neuropathy Market, Sub-Segmentation Of Autonomic Neuropathy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cardiovascular Autonomic Neuropathy
• Gastrointestinal Autonomic Neuropathy
• Genitourinary Autonomic Neuropathy
• 6.8. Global Diabetic Neuropathy Market, Sub-Segmentation Of Proximal Neuropathy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diabetic Amyotrophy
• Lumbosacral Plexus Neuropathy
• 6.9. Global Diabetic Neuropathy Market, Sub-Segmentation Of Focal Neuropathy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cranial Neuropathy
• Cervical Radiculopathy
• Other Focal Neuropathies

7. Diabetic Neuropathy Market Regional And Country Analysis

• 7.1. Global Diabetic Neuropathy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Diabetic Neuropathy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Diabetic Neuropathy Market

• 8.1. Asia-Pacific Diabetic Neuropathy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Diabetic Neuropathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Diabetic Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Diabetic Neuropathy Market

• 9.1. China Diabetic Neuropathy Market Overview
• 9.2. China Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Diabetic Neuropathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Diabetic Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Diabetic Neuropathy Market

• 10.1. India Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Diabetic Neuropathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Diabetic Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Diabetic Neuropathy Market

• 11.1. Japan Diabetic Neuropathy Market Overview
• 11.2. Japan Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Diabetic Neuropathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Diabetic Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Diabetic Neuropathy Market

• 12.1. Australia Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Diabetic Neuropathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Diabetic Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Diabetic Neuropathy Market

• 13.1. Indonesia Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Diabetic Neuropathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Diabetic Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Diabetic Neuropathy Market

• 14.1. South Korea Diabetic Neuropathy Market Overview
• 14.2. South Korea Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Diabetic Neuropathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Diabetic Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Diabetic Neuropathy Market

• 15.1. Western Europe Diabetic Neuropathy Market Overview
• 15.2. Western Europe Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Diabetic Neuropathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Diabetic Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Diabetic Neuropathy Market

• 16.1. UK Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Diabetic Neuropathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Diabetic Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Diabetic Neuropathy Market

• 17.1. Germany Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Diabetic Neuropathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Diabetic Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Diabetic Neuropathy Market

• 18.1. France Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Diabetic Neuropathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Diabetic Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Diabetic Neuropathy Market

• 19.1. Italy Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Diabetic Neuropathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Diabetic Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Diabetic Neuropathy Market

• 20.1. Spain Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Diabetic Neuropathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Diabetic Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Diabetic Neuropathy Market

• 21.1. Eastern Europe Diabetic Neuropathy Market Overview
• 21.2. Eastern Europe Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Diabetic Neuropathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Diabetic Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Diabetic Neuropathy Market

• 22.1. Russia Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Diabetic Neuropathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Diabetic Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Diabetic Neuropathy Market

• 23.1. North America Diabetic Neuropathy Market Overview
• 23.2. North America Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Diabetic Neuropathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Diabetic Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Diabetic Neuropathy Market

• 24.1. USA Diabetic Neuropathy Market Overview
• 24.2. USA Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Diabetic Neuropathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Diabetic Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Diabetic Neuropathy Market

• 25.1. Canada Diabetic Neuropathy Market Overview
• 25.2. Canada Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Diabetic Neuropathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Diabetic Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Diabetic Neuropathy Market

• 26.1. South America Diabetic Neuropathy Market Overview
• 26.2. South America Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Diabetic Neuropathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Diabetic Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Diabetic Neuropathy Market

• 27.1. Brazil Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Diabetic Neuropathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Diabetic Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Diabetic Neuropathy Market

• 28.1. Middle East Diabetic Neuropathy Market Overview
• 28.2. Middle East Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Diabetic Neuropathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Diabetic Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Diabetic Neuropathy Market

• 29.1. Africa Diabetic Neuropathy Market Overview
• 29.2. Africa Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Diabetic Neuropathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Diabetic Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Diabetic Neuropathy Market Competitive Landscape And Company Profiles

• 30.1. Diabetic Neuropathy Market Competitive Landscape
• 30.2. Diabetic Neuropathy Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Daiichi Sankyo Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Depomed Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Diabetic Neuropathy Market Other Major And Innovative Companies

• 31.1. F. Hoffmann-La Roche AG
• 31.2. NeuroMetrix Inc
• 31.3. Lupin Limited
• 31.4. Novartis AG
• 31.5. Boehringer Ingelheim
• 31.6. Regenacy Pharmaceuticals Inc.
• 31.7. Merck & Co. Inc.
• 31.8. Sanofi S.A.
• 31.9. Teva Pharmaceutical Industries Ltd.
• 31.10. AstraZeneca plc
• 31.11. Bayer AG
• 31.12. Bristol-Myers Squibb Company
• 31.13. Merck KGaA
• 31.14. Novo Nordisk A/S
• 31.15. Takeda Pharmaceutical Company Limited

32. Global Diabetic Neuropathy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Diabetic Neuropathy Market

34. Recent Developments In The Diabetic Neuropathy Market

35. Diabetic Neuropathy Market High Potential Countries, Segments and Strategies

• 35.1 Diabetic Neuropathy Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Diabetic Neuropathy Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Diabetic Neuropathy Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer